Patent · US Active

Oligonucleotide analogues targeting human LMNA

US9682097B2 · kind B2 · utility

1Cited by
27References
49Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 11, 2015
Grant dateJun 20, 2017
Priority date—
Expiry dateMay 11, 2035

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2320/33
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Provided are LMNA-targeted antisense oligonucleotides for reducing expression of one or more aberrantly spliced LMNA mRNA isoforms that encode progerin.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.